19.06.2020 Novavax Daily Analysis

19.06.2020 Novavax Daily Analysis

Novavax Inc (NVAX) 59.27, +3.86, +6.97% The shares for Novavax went up with almost 7 percent. This is because the company now has (NASDAQ:NVAX) has a new, high-powered chief medical officer (CMO) Filip Dubovsky who is an industry veteran with more than 20 years of experience, he was most recently deputy CMO for clinical affairs at another global pharmaceutical major, AstraZeneca (NYSE:AZN).Mr Dubosky worked at AstraZeneca for 13 years specializing in MedImmune biologics subsidiary to that, he was the scientific director of the PATH Malaria Vaccine Initiative. That experience promises to be greatly helpful to Novavax; many eyes are on its NVX-CoV2372 vaccine candidate for the still-spreading SARS-CoV-2 coronavirus. The company is also preparing to submit a Biologics License Application to the FDA for NanoFlu, an influenza vaccine for people over 65.